Hosted on MSN6h
FDA approves Vertex non-opioid pain drug
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...
Newly approved painkiller Journavx is 'potentially groundbreaking'
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...
STAT1h
The first shot taken at Medicaid, and Optum’s wellness visit ad
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
3 Magnificent Stocks to Buy and Hold Forever
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...
Vertex stock price target raised to $550 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.
StudyFinds on MSN20h
Journavx: What to know about new FDA-approved non-opioid pain medication
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
GEN1h
Top 10 Takeover Targets of 2025
Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...
New sickle cell treatment approved for NHS use offers patients ‘hope of a cure’
One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...